Promising new developments in cervical cancer

Future Oncol. 2014;10(9):1541-4. doi: 10.2217/fon.14.63.

Abstract

Mary McCormack* speaks to Francesca Lake, Managing Commissioning Editor: Dr McCormack qualified as a doctor from Guy's and St Thomas's Hospital (London, UK) in 1993. She has worked in a variety of London cancer centers and was appointed as a consultant at University College London Hospitals (London, UK) in 2002. She is a clinical oncologist, offering chemotherapy and radiotherapy for gynecological and breast cancers. She is a member of the National Cancer Research Institute Gynecological Clinical Studies Group and the Gynecologic Cancer InterGroup, and is a major contributor to national and international clinical trials. She is also a medical advisor to Jo's Trust and a founding member of Debbie Fund, a University College London-based charity dedicated to raising funds for cervical cancer research.

Keywords: INTERLACE; bevacizumab; cervical cancer; relapsed disease; research.

Publication types

  • Autobiography
  • Biography
  • Historical Article
  • Interview

MeSH terms

  • Female
  • History, 21st Century
  • Humans
  • Ireland
  • London
  • Radiation Oncology
  • Uterine Cervical Neoplasms / therapy*

Personal name as subject

  • Mary McCormack